Who we are
Creating an international ophthalmic R&D company
Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.
Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform.
An innovative therapeutic pipeline
Latanoprostene bunod for IOP lowering in patients with open angle glaucoma or ocular hypertension – Complete Response Letter from the US FDA received on July 21, 2016
AC-170 for allergic conjunctivitis – New Drug Application (NDA) accepted for priority review by the U.S. FDA – PDUFA date: October 18,2016
Nicox across the globe
Nicox is headquartered in Sophia Antipolis (Nice area, France) and is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX).
Nicox has a research center in Bresso (Milan area, Italy) and a US office (Fort Worth, Texas).
Nicox employs around 35 people worldwide.